<DOC>
	<DOCNO>NCT02689752</DOCNO>
	<brief_summary>This open-label , single-center study evaluate pharmacokinetics safety HMPL-013 approximately 6 healthy male subject receive single oral 5mg dose HMPL-013 containing approximately 100 microcuries [ 14C ] HMPL-013 . This study investigate absorption , drug biotransformation mass balance HMPL-013 , seek identify compound 's major metabolite supply information clinical application .</brief_summary>
	<brief_title>A Mass Balance Study Investigate Absorption , Metabolism , Excretion Of 14C Fruquintinib</brief_title>
	<detailed_description>This study open-label , mass balance study fruquintinib administer orally 5mg ( 100mCi ) . Subjects screen eligibility 14 day prior entry study . For study period , subject admit clinical research unit ( CRU ) day dose fast overnight ( approximately 10 hour ) . On morning dosing study period , subject receive single oral dose 5 mg fruquintinib fast state . Subjects remain CRU least 336 hour administration study drug collection serial blood sample pharmacokinetic ( PK ) analysis safety monitoring .</detailed_description>
	<criteria>1 . A Healthy Male Volunteer 18 40 year age inclusive ; 2 . A Body Mass Index ( BMI ) within range 19 25 kg/m2 total body weight &gt; 50kg ; 3 . Medically normal subject significant abnormal finding screen vital sign , physical examination , electrocardiogram ( ECG ) , laboratory parameter evaluate investigator ; 4 . Fertile male subject partner willing undergo contraception follow : condom , contraceptive sponge , contraceptive gel , contraceptive diaphragm , intrauterine device , hormonal contraceptive ( oral injectable ) , subepidermal contraceptive implant contraception method study 1 year take dose investigational product , 5 . Subject must voluntarily consent participate study , provide write informed consent prior start study specific procedure willing comply study procedure . 1 . Subjects family history coronary heart disease ; 2 . Subjects know history bleed gingival hemorrhage , epistaxis hemorrhoid bleed etc . ; 3 . Subjects hypertension ( Systolic Pressure ≥140 mmHg Diastolic Pressure ≥90 mmHg ) ; 4 . Subjects take , take drug affect metabolism prescription medication screen within 30 day prior screen ; Subjects take , take OTC , herbal remedy Vitamin screen within 14 day prior screen ; Subjects take , take plant extract like Hypericum Perforatum L. therapeutic health function affect absorption metabolism screen within 3 day prior screen ; Subjects participate another clinical trial within 2 month prior screen ; 5 . Subjects take , take drug toxicity major organ screen within 3 month prior screen ; 6 . Subjects test positive nicotine screening ca n't quit smoke completely study ; 7 . Subjects history presence clinically significant disease within 3 month prior screen ; 8 . Subjects history presence gastrointestinal , hepatic , renal disease know condition affect absorption , distribution , metabolism excretion investigational product ; 9 . Subjects chronic constipation , diarrhea , irritable bowel syndrome inflammatory bowel disease ; 10 . Subjects hemorrhoids perianal complication regular hematochezia ; 11 . Subjects know history severe allergic reaction drug allergy acute allergic rhinitis food allergy within 14 day prior study medication ; 12 . Subjects donate blood plasma 500ml within 2 month prior study medication 50ml within 14 day prior study medication ; 13 . Subjects positive test hepatitis B ( HBsAg ) hepatitis C ( exclude immunization ) ; 14 . Subjects positive test human immunodeficiency virus ( HIV ) ; 15 . Subjects take vaccination screen within 6 month prior screen ; 16 . Subjects prior history substance abuse treatment ( include alcohol ) ; 17 . Subjects ca n't understand purpose , extent possible outcome study mental disease ; 18 . Adult subject imprison whose freedom restrict administrative problem legal issue ; 19 . Subjects ca n't comply protocol discontinue followup finish study accord protocol ; 20 . Subjects involve study design proceeding investigator , pharmacist , clinical research coordinator related personnel ; 21 . Subjects unsuitable adverse condition determine investigator ; 22 . Subjects participate radiolabeled clinical trial prior study medication ; 23 . Subjects expose significant radiation ( e.g. , xray investigation , CT investigation , one time radiation exposure barium meal examination ) whose occupation require exposure radiation last 12 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>mass balance</keyword>
	<keyword>14C</keyword>
</DOC>